7.88
-0.31(-3.79%)
Currency In USD
| Previous Close | 8.19 |
| Open | 8.15 |
| Day High | 8.15 |
| Day Low | 7.84 |
| 52-Week High | 11.8 |
| 52-Week Low | 4.44 |
| Volume | 37,491 |
| Average Volume | 152,473 |
| Market Cap | 164.64M |
| PE | -6.97 |
| EPS | -1.13 |
| Moving Average 50 Days | 8.77 |
| Moving Average 200 Days | 7.47 |
| Change | -0.31 |
If you invested $1000 in Nuvectis Pharma, Inc. (NVCT) since IPO date, it would be worth $2,424.62 as of July 12, 2025 at a share price of $7.88. Whereas If you bought $1000 worth of Nuvectis Pharma, Inc. (NVCT) shares 2 years ago, it would be worth $522.89 as of July 12, 2025 at a share price of $7.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
GlobeNewswire Inc.
Jul 08, 2025 12:00 PM GMT
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor recep
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
GlobeNewswire Inc.
May 16, 2025 8:35 PM GMT
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
GlobeNewswire Inc.
Apr 29, 2025 8:25 PM GMT
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level